Clinical Trial Evaluating Metronomic Chemotherapy in Patients With Metastatic Osteosarcoma

Summary

Preclinical models show that a daily antiangiogenic regimen at low-dose may be effective against chemotherapy-resistant tumors. The aim of this study is to evaluate the efficacy of maintenance therapy with continuous oral cyclophosphamide and methotrexate in patients with high grade, operable, metastatic osteosarcoma (OST) of the extremities. The primary end point is event-free survival (EFS) from randomization

Timeline

Start

2017-01-02

Primary completion

2019-01-02

Completion

2022-01-31

Drugs

Indications